Amgen/Chugai EPO patent case appeal
Executive Summary
Oral arguments were heard Sept. 7 before three-judge federal appeals panel in Washington, D.C. The judges gave no timetable for a ruling. The companies are appealing a Dec. 11 Boston federal court decision that found certain claims of Amgen and Genetics Institute's patents to be invalid but others to be valid. If that decision is upheld, Amgen would be enjoined from selling Epogen unless it allows Chugai on the market, according to an injunction issued in March.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.